Bristol Myers Squibb Co (BMY)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$59.75
▼ -0.82 (1.35%)
Fair valueFair
$67 +12.1% to fair value
$33fair band $40–$94$100
Day's range
$59.54 – $61.43
52-week range
$40.71 – $67.94
About Bristol Myers Squibb Co
Bristol Myers Squibb is a biopharmaceutical company that researches, develops and sells prescription medicines. Its portfolio focuses on cancer, immune disorders, heart disease and blood conditions. The company earns money by selling branded drugs to wholesalers, hospitals and pharmacies, and by collaborating with other drug makers. Sales are shaped by patent protection, so the loss of exclusivity on a major medicine can reduce revenue, and new drug approvals matter to its outlook.
Over the latest twelve months the company reported revenue of $49.2 billion, and annual revenue rose by 1.4% on average across three years. Profitability at the operating level stands at 27.7%, and return on invested capital came to 19%. The company carries net debt of 2.0 times its EBITDA. A dividend is paid, with a yield of 4.2%. It carries an X-Ray Score of 60 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $40.71 – $67.94Volume 13,770,800Daily, split-adjusted
Vitals
Market cap$122.4B
52-week range$40.71 – $67.94
Volume (last day)13,770,800
P/E (TTM)13.2
EBIT / EV yield8.8%
Free-cash-flow yield9.3%
Dividend yield4.2%
Revenue (TTM)$49.2B
Net income (TTM)$9.3B
Operating margin27.7%
Return on capital19.3%
Debt incl. leases$43.9B
Cash & securities$11.1B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$67model spread $62 – $73
Fair
+12.1% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Multiples use through-the-cycle earnings (0.41x of the last twelve months)
Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened
Price $60
Undervalued < $40Fair $40 – $94Overvalued > $94
10-year DCF (market-scaled)
$99
Peer multiples
$50
Earnings power floor (not blended)
$15
Fundamentals-adjusted multiple
$52
Growth the price implies
2.6%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
82/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield8.8%
Free-cash-flow yield9.3%
Fair value vs price1.1×
Growth
Weak
34/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)1.4%
EPS growth (3y)5.5%
Growth consistency90%
Profitability
Fair
58/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital19.3%
Operating margin27.7%
Gross profitability39.4%
Financial health
Fair
57/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA2.0×
Interest cover7.9×
Dividends
Fair
55/100
Dividend is typical for its sector.
See the numbers →
Dividend yield4.2%
Dividends vs free cash flow45%
Dividend growth2.9%
Quarterly results: last 6 quarters
-5.6%
Mar '25
+0.6%
Jun '25
+2.8%
Sep '25
+1.3%
Dec '25
+2.6%
Mar '26
+5.7%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $13.0B, diluted EPS $1.62.
Compare with peers
ZTS Zoetis Inc.68 LLY ELI LILLY & Co61 JNJ Johnson & Johnson50 MRK Merck & Co., Inc.32Other Pharmaceuticals companies by X-Ray Score.
Fundamentals checklist
● 6 Good · ● 9 Average · ● 1 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldGood
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyAverage
Balance sheet
Current ratioAverage
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 62/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Operating income | $9.4B | $8.9B | $9.6B | −$6.4B | $11.2B |
| Net income | $7.0B | $6.3B | $8.0B | −$8.9B | $7.1B |
| Operating cash flow | $16.2B | $13.1B | $13.9B | $15.2B | $14.2B |
| Operating margin | 20.3% | 19.4% | 21.3% | -13.3% | 23.3% |
| Free cash flow | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B |
| Diluted EPS | $3.12 | $2.95 | $3.86 | $-4.41 | $3.46 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bearish
4 bullish · 4 neutral · 8 bearish
Weekly
Neutral
6 bullish · 1 neutral · 5 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 59.07 | Bullish |
| EMA 10 | 59.52 | Bullish |
| SMA 20 | 60.35 | Bearish |
| EMA 20 | 60.35 | Bearish |
| SMA 50 | 62.99 | Bearish |
| EMA 50 | 61.37 | Bearish |
| SMA 100 | 60.34 | Bearish |
| EMA 100 | 60.55 | Bearish |
| SMA 200 | 58.48 | Bullish |
| EMA 200 | 58.01 | Bullish |
Oscillators (daily)
| RSI (14) | 45.49 | Neutral |
| MACD (12, 26) | -1.09 | Bearish |
| Momentum (12) | -3.26 | Bearish |
| Stochastic %K (14) | 49.16 | Neutral |
| Williams %R (14) | -50.84 | Neutral |
| CCI (20) | -8.91 | Neutral |
Pivot points (classic, last session)
S3 57.16 | S2 58.35 | S1 59.05 | Pivot 60.24 | R1 60.94 | R2 62.13 | R3 62.83 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.52 USD
Yield on today's price
4.22%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 2 Oct 2026 | 0.6300 |
| 2 Jul 2026 | 0.6300 |
| 2 Apr 2026 | 0.6300 |
| 2 Jan 2026 | 0.6300 |
| 3 Oct 2025 | 0.6200 |
| 3 Jul 2025 | 0.6200 |
| 4 Apr 2025 | 0.6200 |
| 3 Jan 2025 | 0.6200 |
| 4 Oct 2024 | 0.6000 |
| 5 Jul 2024 | 0.6000 |
| 4 Apr 2024 | 0.6000 |
| 4 Jan 2024 | 0.6000 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
BMY SEC filings
30 Jul 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
8 May 2026
8-KSEC EDGAR
Shareholder vote results
30 Apr 2026
10-QSEC EDGAR
Quarterly report
30 Apr 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
25 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
11 Feb 2026
10-KSEC EDGAR
Annual report
5 Feb 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.